The risk of skin cancer is highly increased in kidney-transplant recipients, but the risk of subsequent skin cancers is less well studied. The aim of this study was to estimate 
Introduction
The highly increased risk of non-melanocytic skin cancer (NMSC) in organ-transplant recipients (OTR) due to long-term use of immunosuppressive drugs has been frequently reported (1) (2) (3) (4) (5) (6) (7) (8) . The cumulative incidence of NMSC rises with increasing time after transplantation (1, 2, 6, (9) (10) (11) . Most studies, however, focused only on the first squamouscell carcinoma (SCC) or basal-cell carcinoma (BCC). The risk to develop subsequent SCC or BCC in OTR has been scarcely studied (5, (11) (12) (13) . A Scandinavian study showed that 25% of OTR with a first NMSC will develop a second lesion within 13 months, and 50% within 3.5 years (5) . A British study reported a mean interval of 15 months between detection of the first and second cancers, and 11 months between the second and third (13) . A French study showed that 34% of the 67 heart-transplant recipients and 52% of the 121 kidney-transplant recipients (KTR) with a first SCC developed a subsequent SCC within 3 years after the first SCC. After 5 years these percentages had risen to 64% and 67% in HTR and KTR, respectively (12) . A recent study in New Zealand showed that virtually all 96 KTR with skin cancer developed multiple NMSC. After 1 year approximately 30%, after 2 years 50%, after 3 years 60% and after 5 years 80% had developed subsequent NMSC after the first skin cancer (11) . Compared with the general population these percentages are very high, since the 3-year cumulative risk of a subsequent SCC after a first SCC in the general population is 18% (14) . The risk of a subsequent BCC after the first BCC has not been reported in OTR. In the general population, nearly 50% of patients routinely treated for BCC developed multiple primary BCC during 10 years of observation (15, 16) . A meta-analysis of 7 independent studies showed a mean 3 year risk of 44% after an initial diagnosis of BCC (14) .
The most important factors that favor the development of SCC after transplantation are older age at transplantation, male sex, fair skin type, high cumulative sunlight exposure and length and level of immunosuppression (2, 6, 8, 9, (17) (18) (19) (20) (21) . The risk of BCC is more strongly associated with intermittent, intense sunlight exposure (e.g., sunburn, childhood exposure) (22, 23) . Other risk factors for BCC are older age at transplantation, fair skin type and immunosuppressive treatment (2, 8, 21, (24) (25) (26) (27) . Risk factors for subsequent skin cancers are transplantation before 1984, multiple skin cancers at first consultation, hazel-light eye color and advanced age at diagnosis of the first skin cancer (11, 12) .
Better understanding of the risk of a subsequent SCC and BCC in KTR would help in the design of a more rational follow-up of these patients. The aim of this study was to estimate the cumulative incidence of a second SCC or BCC following the occurrence of the first skin cancer in a cohort of KTR and to study risk factors for the development of subsequent skin cancers. Most of these patients were regularly followed at the department of Nephrology.
Those with cutaneous problems were also seen at the department of Dermatology. At each visit to the skin clinic the entire skin was checked for skin problems. Special attention was focused on the possible presence of keratotic skin lesions and skin cancers. Only few patients were primarily followed by dermatologists in other hospitals than the LUMC.
The following baseline characteristics were recorded for each KTR: sex and dates of birth, transplantation, death, or last follow-up. The risk factors studied in the patients with multiple skin cancers compared to those with a single skin cancer were sex, age, number of years on immunosuppression, country of origin, type of maintenance immunosuppressive therapy, induction and rejection therapy, donor type (living or cadaver), HLA-mismatching and the year the transplantation had been performed. Data about sun exposure and skin type were not collected, because this would have been only possible by questionnaire or physical examination in the living patients. The study adhered to the Declaration of Helsinki Principles and the medical ethical committee of the LUMC had approved the study design.
Data collection: registration of histological diagnoses
All histological diagnoses were systematically computerized at the department of Pathology since 1984 and diagnoses before 1984 were computerized retrospectively starting with the biopsies performed in 1970. In the period between 1966 and 1970 no skin cancers had been diagnosed, which was checked by hand searching in the medical charts of the KTR transplanted before 1970. Dates of the biopsies, locations of the lesions and the histological diagnoses were documented. Routinely, the initial biopsy was followed by an excision and in some cases by a re-excision. In those cases, only the first histologically confirmed diagnosis of this specific skin cancer was taken into account, to prevent double counting. In-situ carcinomas (Bowen's disease), precursor lesions (actinic keratoses and keratoacanthomas) and skin cancers other than squamous-cell and basal-cell carcinoma (e.g. malignant melanoma, Kaposi sarcoma and adnex carcinomas) were not considered in this study.
The country of origin was used as a rough estimation of skin type. Information about the initial and maintenance immunosuppressive therapy of the patients with Kaplan Meier survival analyses were used to estimate the cumulative incidences of skin cancer after transplantation. As opening dates for these analyses we used the date of the first transplantation; as closing dates we used the date of diagnosis of the first skin cancer, the date of the patient's death or the date of last follow up. Skin cancers before transplantation were not considered in these analyses. Patients were not censored from the analyses at graft failure. Differences between patients with and without skin cancer were analyzed by Chi-square for categorical variables and Student's T-tests for continuous variables.
For the analyses of subsequent skin cancers in patients with skin cancer we used the 222 patients with NMSC who were diagnosed at the LUMC. Kaplan Meier survival analyses were used to estimate the cumulative incidence of subsequent skin cancers in patients with a prior skin cancer. Cox proportional hazard analyses were used to identify potential risk factors of NMSC multiplicity. As opening dates for both analyses we used the date of the first skin cancer; as closing dates we used the date of diagnosis subsequent skin cancers in kidney-transplant recipients 54 of the subsequent SCC or BCC, the date of the patient's death, the date of last follow up, the date that they were lost to follow-up, or we used the date of the end of the study (June 1, 2007). Some patients had two NMSC at the time that they presented themselves with the first NMSC. In these patients the third NMSC was counted as the second presentation of NMSC.
The initial and maintenance immunosuppressive therapies were categorized into three basic treatment groups: duo or triple therapy with Aza in any combination; duo or triple therapy with MMF in any combination; and duo therapy without Aza or MMF (i.e. a combination of prednisolone with CsA). If no data were available for the maintenance immunosuppressive therapy the data of the initial immunosuppressive therapy were used. For all our analyses with immunosuppressive therapy, we used the sub-categorization of the maintenance therapy because the patients were, generally, most prolonged exposed to this regimen.
Because ATG and OKT3 exert by far the highest immunosuppressive effect, induction and rejection treatments were dichotomized into those with and without ATG and/or OKT3. Because the biological effects of ATG and OKT3 are supposed to be similar before and after the transplantation, exposures to ATG and/or OKT3 as induction or rejection treatment were also combined for our analyses.
Statistical analyses were performed with SPSS software (version 16.0, SPSS, Chicago, IL). Table 1 . Eight out of the 239 patients (3.3%) had developed the first skin cancer before transplantation (2 both SCC and BCC, 6 only BCC), with a median time of 1.3 years before transplantation ( Table 1 ). The majority of the patients with NMSC were transplanted before 1986, whereas patients without skin cancer were more frequently transplanted after 1986 (Table 1, P<0.001). The follow-up period of the KTR with skin cancer was, therefore, much longer (p = 0.001).
Results

Baseline characteristics
The sex distribution did not differ between patients with and without skin cancer (p = 0.218) ( Table 1 ). In the Cox proportional hazard model older age at transplantation was associated with a significantly increased risk of skin cancer (3.6% [95% CI 2.6%;4.7%] increase for each additional year of age, P < 0.001). After stratification for time period after transplantation this association was also clear in Table 1 . The median age at chapter 3 which the KTR developed their first NMSC was 53.3 years. There were 9 patients who died of metastases of SCC (5 times the SCC was located on the arm or shoulder and 4 times the location was in the face, on the ear, or on the skull). None of the patients died of BCC.
subsequent skin cancers in kidney-transplant recipients NMSC, non-melanocytic skin cancer; SCC, squamous-cell carcinoma; BCC, basal-cell carcinoma; KT, kidney transplantation. * Some patients had both SCC and BCC. This fact is reflected here by overlapping of the numbers of patients in these categories.
The cumulative incidence of NMSC after transplantation was 9% after 10 years, 24% after 20 years and 40% after 30 years. For SCC this incidence was 6%, 19%, and 33% and for BCC 5%, 14% and 24% after these time periods, respectively. This is graphically presented in the supplementary Figure. The cumulative incidence of a second NMSC after the first NMSC increased from 32% after 1 year to 59% after 3 years and 72% after 5 years (Figure 1 ). The cumulative incidences for a second SCC were 31%, 62% and 75%, respectively. The cumulative incidences for a second BCC were lower and were 16%, 37% and 51% after these time periods, respectively ( Figure 1 ).
The distribution of SCC and BCC on the body is presented in Table 2 . When patients developed only one SCC this tumor was more frequently located on the head and neck, whereas subsequent SCC were more common on the hands and fingers.
Approximately 50% of the BCC were located on the head and neck in both patients with only one BCC as patients with subsequent BCC. Patients with one BCC developed the tumor more frequently on the hands and fingers and patients with multiple BCC developed them more frequently on the trunk ( Table 2 ).
The risk of SCC and BCC in KTR with SCC or BCC as first NMSC
A total of 127 KTR started with SCC as the first skin cancer. Hundred (78.7%) of them developed a second SCC and 41 (32.3%) developed a first BCC at a later time point.
Altogether 95 KTR started with BCC as the first skin cancer of whom 54 (56.8%) developed a second BCC and 41 (43.2%) a first SCC at a later time point. We asked the question whether it would be relevant for the risk and type of subsequent skin cancers if the first skin cancer would be SCC or BCC. Numbers of KTR at risk at the speci ed time periods after transplantation (yrs) Figure 2A shows that KTR who started with SCC mainly developed SCC as second skin cancer and Figure 2B shows that KTR who started with BCC mainly developed BCC as second skin cancer. After the development of the first SCC in the latter group of patients, the risk of subsequent SCC was similar to the risk of subsequent SCC in the KTR who started with SCC.
Risk factors for subsequent skin cancers
The distribution of potential risk factors in the patients with one and those with subsequent SCC or BCC and the results of univariate analyses are presented in Table 3 .
Multivariate analyses are presented in Table 4 . In both types of analyses maintenance immunosuppressive therapy with Aza was associated with the highest risk of subsequent SCC, but not of subsequent BCC. Patients who were immunosuppressed with CsA had a significantly reduced risk of subsequent SCC compared to patients who were immunosuppressed with Aza (Tables 3 and 4) . A potentially decreased risk of MMF could not be assessed, because of insufficient patients in this treatment category.
In the univariate analyses the time period of transplantation between 1986 and 1995 was associated with a reduced risk of subsequent SCC (Table 3) , but this reduced risk disappeared in the multivariate analyses (Table 4 ). In contrast, the risk of subsequent BCC tended to increase in the later time periods, although significance was not reached (Table 4) . Age at transplantation, which is a risk factor for the first skin cancer, was not a statistically significant risk factor for subsequent SCC or BCC (Table 3) , although there was a trend of an association between older age and skin cancer in the multivariate analyses (Table 4) . Patients with a longer time between the transplantation and the development of the first SCC had an increased risk of developing subsequent SCC, but the time between transplantation and the first BCC did not influence the development of subsequent BCC (Tables 3 and 4) . Numbers of KTR at risk at the speci ed time periods after transplantation (yrs) Patients who were transplanted with a kidney of a living donor had an increased risk of subsequent BCC compared to patients who received a cadaver kidney (Table 4) .
Donor type did not affect the risk of subsequent SCC. Numbers of KTR at risk at the speci ed time periods after transplantation (yrs) Table 3 Risk factors for subsequent squamous-cell carcinomas or basal-cell carcinomas, univariate analyses, continued. ATG, anti-thymocyte globulin; Aza, azathioprine; BCC, basal cell carcinoma; CsA, cyclosporine A; MMF, mycofenolatemofetil; P, prednisolone; SCC, squamous cell carcinoma; Tac, tacrolimus; OKT3, muronomab-CD3; CI, confidence interval. #Duo-therapy with P and Aza was given to all patients with the exception of one patient with BCC who was treated with P, Aza and CsA. ##Duo-therapy with P and MMF was given to 5 patients, triple therapy with P, MMF and CsA to 7 patients and with P, MMF and Tac to 3 patients. ###Duo-therapy with P and CsA was given to all patients in this category.
* When there were less than 7 patients in both categories together, the hazard ratio was not calculated. Statistically significant hazard ratios are indicated in italic. ATG, anti-thymocyte globulin; Aza, azathioprine; BCC, basal cell carcinoma; CsA, cyclosporine A; MMF, mycofenolatemofetil; P, prednisolone; SCC, squamous cell carcinoma; Tac, tacrolimus; OKT3, muronomab-CD3; CI, confidence interval. * Adjusted for age at transplantation, sex, donor type, year of transplantation, time to first skin cancer, ATG or OKT3 as induction or rejection treatment and maintenance immunosuppression. ** When there were less than 7 patients in both categories together, the hazard ratio was not calculated. Statistically significant hazard ratios are indicated in italic.
Male sex and ATG or OKT3 as induction or rejection therapy were not significantly associated with an increased risk of subsequent SCC or BCC (Tables 3 and 4) . HLAmismatching also did not influence the risk of subsequent SCC or BCC (data not shown). Country of origin was not analyzed as a risk factor, since all patients with SCC originated from the Netherlands and only two of the patients with BCC originated from another country, namely China and Turkey, respectively.
Discussion
This study confirms the high risk of subsequent NMSC in KTR who have developed a first NMSC. This risk was especially high for SCC but was also substantial for BCC. The tumor burden was very high in these patients with 24% of KTR developing 10 or more skin cancers within a short time period. The high risk of subsequent SCC was only apparent after the appearance of a first SCC: the risk of SCC was much lower in the KTR who presented themselves with BCC, but after the appearance of the first SCC subsequent SCC appeared equally fast in the latter group.
The 3-year risks of 59% of NMSC and 62% of subsequent SCC in our study are comparable with the risks of 60% of NMSC in New Zealand (11) and 52% of SCC in France (12) and the 5 year-risks of 72% of NMSC and 75% of SCC in our study are comparable with the risks of 80% of NMSC in New Zealand (11) and 67% of SCC in France (12) . The risk of subsequent SCC in KTR is much higher compared with the general population, in which a 3-year cumulative risk of subsequent SCC of only 18% was calculated (14) .
There are no previous studies describing the risk of subsequent BCC in KTR. to patients who are immunosuppressed with other drugs (10, 29) . Aza has been recognized to increase photosensitivity of the skin and also enables UVA to directly damage DNA (30) . These characteristics of Aza may increase the risk of both first and subsequent SCC in patients who are chronically using this drug.
Longer time periods between transplantation and the development of the first SCC were associated with an increased risk of subsequent SCC. Apparently, the duration of the immunosuppressive therapy influences the development of subsequent SCC after the first SCC. The induction period of the first BCC did not influence the development of subsequent BCC.
Male sex has been reported as a risk factor for multiple skin cancers (12, 16 ), but we only observed a trend of an increased risk of multiple BCC for male patients. A kidney of a living donor compared with a cadaver kidney was associated with an increased risk of subsequent BCC but not of subsequent SCC. Additional studies are needed to confirm this association.
Sun exposure has been reported as an important risk factor for multiple lesions (21, 31) and Euvrard et al showed that light color of the hair and eyes and fair skin type were predictive of multiple SCC (12) . In our study we were not able to assess these risk factors.
In conclusion, this study confirmed and consolidate that skin cancer multiplicity, in particular of SCC, is very common in KTR. Transplant physicians should be aware of this problem and easy accessible reference of KTR to the dermatologist should be accomplished. KTR with a first skin cancer should be carefully checked for subsequent skin cancers, preferably at dermatology departments with specialized skin cancer care.
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